Sectors

BDX
Becton, Dickinson and Company
151.62
1 x 151.59
1 x 151.69
bid
ask
-
2.21
1.44%
02:34 PM
timesize
Ytd-21.87%
1y-14.38%
148.34
day range
151.90
127.59
52 week range
187.35
Open151.83Prev Close153.83Low148.34High151.90Mkt Cap55.73B
Vol971.67KAvg Vol2.96MEPS13.45P/E11.44Forward P/E11.34
Beta0.21Short Ratio3.87Inst. Own99.02%Dividend4.20Div Yield2.78
Ex Div Date06-09Earning08-0650-d Avg148.06200-d Avg154.291yr Est176.92
Earning
DateForEstimateReportedSurprisesurprise %
2026-05-072026-032.772.90.134.69%
2026-02-092025-122.822.910.093.19%
2025-11-062025-093.923.960.041.02%
2025-08-072025-063.423.680.267.60%
2025-05-012025-033.283.350.072.13%
2025-02-052024-122.983.430.4515.10%
Upgrade / Downgrade
DateFirmActionFromTo
2026-07-06Evercore ISI GroupUpgradeOutperformOutperform
2026-05-11BarclaysUpgradeOverweightOverweight
2026-05-08Wells FargoUpgradeEqual-WeightEqual-Weight
2026-05-04TD CowenUpgradeHoldHold
2026-04-17Piper SandlerUpgradeNeutralNeutral
2026-03-23Argus ResearchUpgradeBuyBuy
Profile
Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.
Insider Holder
DateNameRelationQuantityDescription
2025-11-25DELOREFICE CHRISTOPHERChief Financial Officer22.98KStock Award(Grant)
2026-06-25FELD MICHAELOfficer21.01KSale
2025-09-09FRASER CLAIREDirector22.23KSale
2025-11-25GOETTE ROLANDOfficer18.78KStock Award(Grant)
2026-01-26JONES CHRISTOPHER IAN MONTAGUEDirector24.30KStock Award(Grant)
2026-06-30MUHSIN BILALOfficer41.36KStock Award(Grant)
Institution Ownership
Report DateOrganizationPositionValuePercentage
2026-03-30Blackrock Inc.26.15M3.97B9.49%
2026-03-30Vanguard Capital Management LLC18.49M2.81B6.71%
2026-03-30Vanguard Portfolio Management LLC15.32M2.33B5.56%
2026-03-30State Street Corporation13.82M2.10B5.02%
2026-03-30First Eagle Investment Management, LLC11.93M1.81B4.33%
2026-03-30Invesco Ltd.10.17M1.55B3.69%
Fund Ownership
Report DateOrganizationPositionValuePercentage
2026-03-30VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund9.04M1.37B3.28%
2026-04-29First Eagle Funds-First Eagle Global Fund8.06M1.22B2.92%
2026-03-30VANGUARD INDEX FUNDS-Vanguard 500 Index Fund7.24M1.10B2.63%
2026-03-30VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund6.15M934.33M2.23%
2026-03-30T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App5.80M880.66M2.10%
2026-05-30iShares Trust-iShares Core S&P 500 ETF3.75M569.99M1.36%
Dividend
DividendDate
1.052026-06-09
1.052026-03-10
1.052025-12-08
1.042025-09-08
1.042025-06-09
1.042025-03-10
Split
SplitDate
1025 : 10002022-04-01
2 : 11998-08-21
2 : 11996-08-16
2 : 11993-03-01
2 : 11986-03-03